In the EMPOWER trials, emraclidine was well-tolerated with a safety profile comparable to that observed in the Phase 1b trial. The most commonly reported adverse events in EMPOWER-1 and EMPOWER-2, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback